Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
The purpose of this study is to study the effect of hormone therapies (androgen pathway
modification) on the outcomes of patients with lung cancer. This information may be of
benefit for future treatment strategies, prevention and control.
In this study, the protein where testosterone binds, called the androgen receptor (AR), will
be measured in samples from the patient's biopsy and surgical tumour samples. The
investigators will look at a marker of how fast the cancer is growing (Ki67) before using
finasteride from your biopsy specimen. Finasteride will be taken from the day of consent
until the day of the patient's surgery. This marker will be measured again after using
finasteride from the surgical specimen. The investigators will be looking for a decrease in
the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that
this medication is blocking tumour growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society